A new phase 2 clinical trial published in Nature Medicine is exploring a powerful new way to treat obesity. Researchers studied whether combining the experimental drug bimagrumab with semaglutide also known as Ozempic could improve weight loss and body composition compared to semaglutide alone. The results suggest this combination may help people lose more fat while protecting muscle — an important breakthrough in obesity care.
Why Obesity Treatment Needs Better Options
Obesity is a chronic disease that increases the risk of heart disease, diabetes, stroke, and many other health problems. Medications like semaglutide have changed how we treat obesity by helping people lose significant weight.
However, when people lose weight — especially quickly — they do not just lose fat. They also lose lean body mass, which includes muscle. Losing too much muscle can affect strength, metabolism, and long-term health.
That is where as of 2026, an experimental drug called bimagrumab may help.
Bimagrumab is a monoclonal antibody designed to block certain receptors involved in muscle regulation. Earlier research has shown that it can reduce fat mass and increase or preserve muscle mass. Researchers wanted to see if combining bimagrumab with semaglutide could improve overall results.
What Are Semaglutide and Bimagrumab?
Semaglutide (also known as Ozempic) is a GLP-1 receptor agonist. It works by:
- Reducing appetite
- Slowing stomach emptying
- Helping people feel full longer
It is already approved for weight management.
Bimagrumab, an experimental drug, works differently. It blocks activin type II receptors, which are involved in regulating muscle and fat tissue. By blocking these signals, bimagrumab may:
- Increase or preserve lean muscle mass
- Reduce fat mass
- Improve body composition
Because the two drugs work through different pathways, researchers believed they might complement each other.
How the Phase 2 Trial Was Designed
This was a randomized, controlled phase 2 clinical trial in adults with obesity or overweight. Phase 2 means that this is an early study done for purposes of finding if the drug works and is initially deemed as safe.
Participants were assigned to one of several groups:
- Semaglutide alone
- Bimagrumab alone
- Combination of bimagrumab plus semaglutide
- Placebo
The study lasted 48 weeks. Researchers measured:
- Total body weight loss
- Changes in fat mass
- Changes in lean mass (muscle)
- Safety and side effects
Body composition was carefully analyzed to understand how much weight loss came from fat versus muscle.
What Did the Study Find?
The combination of bimagrumab plus semaglutide produced greater improvements in body composition compared with semaglutide alone.
Key findings included:
- Participants receiving the combination experienced substantial weight loss.
- The combination led to greater fat mass reduction.
- Importantly, lean mass was better preserved compared to semaglutide alone.
While semaglutide alone led to meaningful weight loss, some of that loss included lean mass. In contrast, adding bimagrumab appeared to shift the balance more toward fat loss while maintaining muscle.
This is important because preserving muscle during weight loss may help maintain metabolic health and physical function.
The safety profile of the combination was generally consistent with what is already known about these medications. Gastrointestinal side effects — common with GLP-1 drugs like semaglutide — were observed. Researchers carefully monitored adverse events throughout the study.
Because this was a phase 2 trial, it was designed to evaluate effectiveness and safety before larger phase 3 studies.
Why Body Composition Matters More Than the Scale
Most people focus only on the number on the scale. But from a medical standpoint, what kind of weight is lost matters just as much as how much is lost.
Fat loss improves:
- Insulin sensitivity
- Blood pressure
- Cholesterol levels
- Inflammation
Muscle mass, on the other hand, supports:
- Strength and mobility
- Metabolic rate
- Long-term weight maintenance
The combination therapy in this trial suggests a possible shift toward more targeted fat loss while protecting lean mass.
What This Could Mean for the Future of Obesity Treatment
This research represents an important step forward in obesity medicine.
Current GLP-1–based therapies are effective, but researchers are now looking at ways to:
- Improve fat loss
- Protect muscle
- Enhance metabolic benefits
- Personalize treatment
The results of this phase 2 trial suggest that targeting multiple biological pathways at once may improve outcomes.
However, more research is needed. Larger phase 3 trials will be required to confirm:
- Long-term safety
- Durability of weight loss
- Cardiometabolic outcomes
- Real-world effectiveness
If future studies confirm these findings, combination therapies like bimagrumab plus semaglutide could represent a new generation of obesity treatment focused not just on weight loss, but on healthier body composition.
A Shift Toward Smarter Weight Loss
Obesity treatment is evolving. Instead of simply asking, “How much weight did someone lose?” researchers are now asking, “What kind of weight was lost?”
This phase 2 study highlights a promising strategy: combining medications that work in different ways to improve results. Protecting muscle while reducing fat could help patients achieve healthier, more sustainable outcomes.
While this is still research and not yet a standard treatment, the findings open the door to more advanced, science-based approaches to obesity care.
Source:
Garvey WT, et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nat Med. 2026. Accessed by: https://www.nature.com/articles/s41591-026-04204-0
